跳至主要内容
临床试验/NCT00751829
NCT00751829已完成3 期

Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company0 个研究点目标入组 417 人开始时间: 2003年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
417
主要终点
Change in mean sitting systolic blood pressure as assessed by conventional BP measurements

研究概览

简要总结

To evaluate the efficacy of long-term treatment of individually optimized doses of olmesartan medoxomil compared to nitrendipine in elderly and very elderly patients with isolated systolic hypertension. The study hypothesis is non-inferiority of olmesartan medoxomil compared to nitrendipine in lowering mean sitting systolic blood pressure after 12 weeks of treatment compared to baseline. The study duration is up to 32 weeks, including a 24-week treatment period. After 12 weeks hydrochlorothiazide may be added to control blood pressure. Efficacy and safety measurements are carried out at up to 15 visits during the trial period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 65 or older
  • Mean sitting BP >160 mmHg and mean sitting dBP<90 mmHg

排除标准

  • Secondary hypertension
  • Malignant hypertension
  • Severe Heart Failure (NYHA III-IV)
  • Recent history of myocardial infarction
  • Hypersensitivity to study medications
  • History of drug or alcohol abuse
  • History or evidence of renal disease

研究组 & 干预措施

1

Experimental

oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP

干预措施: olmesartan medoxomil + hydrochlorothiazide, if necessary (Drug)

2

Active Comparator

oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP

干预措施: nitrendipine + hydrochlorothiazide, if necessary (Drug)

结局指标

主要结局

Change in mean sitting systolic blood pressure as assessed by conventional BP measurements

时间窗: 12 weeks

次要结局

  • Change in mean standing systolic BP, mean sitting diastolic BP and mean standing diastolic BP(after 1, 2, 4, 8, 12, 16, 20, and 24 weeks of treatment)
  • Change in mean sitting systolic blood pressure assessed by conventional BP measurements(After 1, 2, 4, 8, 12, 16, 20, and 24 weeks)

研究者

发起方
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
申办方类型
Industry

相似试验